Eye Disorders clinical trials

Explore recruiting eye disorders clinical trials.

Recruiting eye disorders studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Eye Disorders trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study to test how well different doses of BI 1584862 are tolerated by healthy men

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

LOADEX: PILOT AND PHASE 2 STUDY OF THE EFFICACY OF A TREATMENT PROTOCOL WITH DEXAMETHASONE IMPLANT LOADING DOSE IN PATIENTS WITH DIABETIC MACULAR EDEMA

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

France, Germany, Greece, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

Poland, Bulgaria, Germany, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Non-inferiority Clinical Trial for Comparing the Efficacy and Tolerability of a new fixed-Combination Generic Formulation of Brimonidine 0.2%/Timolol 0.5% eye drops, solution in single-dose containers vs Combigan® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension

Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Eye Disorders trials by city

Eye Disorders in Toronto Eye Disorders in Vancouver Eye Disorders in Montreal Eye Disorders in Calgary Eye Disorders in Edmonton Eye Disorders in Ottawa Eye Disorders in Winnipeg Eye Disorders in Quebec City Eye Disorders in Hamilton Eye Disorders in Kitchener Eye Disorders in London Eye Disorders in Halifax Eye Disorders in New York Eye Disorders in Los Angeles Eye Disorders in Chicago Eye Disorders in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease